Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation
Recruiting
N/A
Interventional Study
Depression
Depressive Disorder
Overweight or Obesity
Depressive Symptoms
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 200 (estimated)
- Sponsor
- Riphah International University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patient…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
INCLUSION CRITERIA Group I: Normal Controls Group II: Depression Group III: Obesity
Group IV and V:
* Age ≥ 18 years
* Both males and females
* Recurrent depressive disorder (6A71) according to ICD-11,
* Asian cut off: Obese and overweight (BMI \< 23)
* BDI score ≥ 13 or PHQ score ≥ 4
* Either med…
Contacts